Court Ruling Pressures Stem Cell Stocks
Companies involved in researching medical techniques using stem cells saw shares tumble across the board Tuesday, a day after a federal court ruled to block government funding for stem cell research.
Geron
FDA OKs First Trial of Stem Cells to Heal Spine Injuries
The Food and Drug Administration cleared the way on Friday for California biotech firm Geron to begin human clinical trials of its experimental embryonic stem cell-based therapy to heal spinal cord injuries in paraplegic patients. Geron claims this is the first such trial in humans.
Geron to Test Embryonic Stem-Cell Therapy After FDA Lifts Clinical Hold; Shares Soar
Pharmaceutical company Geron announced that the U.S. Food and Drug Administration has lifted the clinical hold it had placed on the company's new drug application, allowing it to proceed with a clinical trial of GRNOPC1 in patients suffering from acute spinal cord injury.
Pfizer Invests in Stem Cell Therapy
Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.
